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Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and 
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Abstract 
Background The benefits of aerobic exercise (AE) for cardiovascular disease (CVD) have been well 
documented. Resistance exercise (RE) has been traditionally examined for its effects on bone density, 
physical function, or metabolic health, yet few data exist regarding the benefits of RE, independent of and 
combined with AE, for CVD prevention. This randomized controlled trial, “Comparison of the 
Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise (CardioRACE),” is designed to 
determine the relative benefits of RE, AE, or combined RE plus AE training on CVD risk factors. 
Methods Participants are 406 inactive men and women (35-70 years) with a body mass index of 25-40 
kg/m2 and blood pressure (BP) of 120-139/80-89 mm Hg without taking antihypertensive medications. 
Participants are randomly assigned to RE only, AE only, combined RE and AE (CE), or a no exercise control 
group. Participants perform supervised exercise at 50%-80% of their relative maximum intensity for both 
AE and RE, 3 times a week for 60 minutes per session, for 1 year (all 3 groups are time matched). 
Results The primary outcome is a composite z score including resting BP, low-density lipoprotein 
cholesterol (LDL-C), fasting glucose, and percent body fat, which is assessed at baseline, 6 months, and 
12 months. Diet and outside physical activity are measured throughout the intervention for 1 year. 
Conclusion CardioRACE (ClinicalTrials.gov NCT03069092) will fill an important knowledge gap regarding 
the effects of RE, alone or in addition to the well-documented effects of AE. CardioRACE will help 
generate more comprehensive and synergistic clinical and public health strategies to prevent CVD. 
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Abstract
Background: The benefits of aerobic exercise (AE) for cardiovascular disease (CVD) have been 
well documented. Resistance exercise (RE) has been traditionally examined for its effects on bone 
density, physical function, or metabolic health, yet few data exist regarding the benefits of RE, 
independent of and combined with AE, for CVD prevention. This randomized controlled trial, 
“Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise 
(CardioRACE),” is designed to determine the relative benefits of RE, AE, or combined RE plus 
AE training on CVD risk factors.
Methods: Participants are 406 inactive men and women (35–70 years) with a body mass index of 
25–40 kg/m2 and blood pressure (BP) of 120–139/80–89 mmHg without taking antihypertensive 
medications. Participants are randomly assigned to RE only, AE only, combined RE and AE (CE), 
or a no exercise control group. Participants perform supervised exercise at 50%–80% of their 
relative maximum intensity for both AE and RE, 3 times/week for 60 minutes/session for 1 year 
(all 3 groups are time-matched).
Results: The primary outcome is a composite z-score including resting BP, low-density 
lipoprotein cholesterol (LDL-C), fasting glucose, and percent body fat, which is assessed at 
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baseline, 6-months, and 12-months. Diet and outside physical activity are measured throughout the 
intervention for 1 year.
Conclusion: CardioRACE (ClinicalTrials.gov ) will fill an important knowledge gap regarding 
the effects of RE, alone or in addition to, the well-documented effects of AE. CardioRACE will 
help generate more comprehensive and synergistic clinical and public health strategies to prevent 
CVD.
Keywords
training; blood pressure; cholesterol; physical activity; strength; weight
INTRODUCTION
One out of three deaths is caused by cardiovascular disease (CVD), and one out of four 
individuals in the United States (US) are currently living with some form of CVD.1 The 
economic impact of CVD is estimated at $330 billion per year.1 This will increase to an 
estimated $749 billion in 2035, since approximately half of the current adult population in 
the US has high blood pressure (BP), defined as a systolic/diastolic BP of ≥130/80 mmHg 
according to 2017 guidelines.1,2 There is an obvious need for well-defined lifestyle 
interventions, such as exercise and diet, to mitigate the rising costs and burdens associated 
with CVD.
Physical activity (PA), particularly aerobic exercises (AE) such as brisk walking or jogging, 
is well established as an effective method to prevent and treat CVD. The current federal 
Physical Activity Guidelines (PAG)state that adults should obtain at least 150 minutes per 
week of moderate-intensity or 75 minutes per week of vigorous-intensity aerobic PA to 
significantly reduce their risk of CVD. There are also simpler guidelines to perform 
resistance exercise (RE), such as weight lifting, on ≥2 days per week.3 RE provides bone, 
muscle, and metabolic health benefits; however, limited evidence of RE’s efficacy, 
independent of and combined with AE, on CVD risk factors has precluded the development 
and dissemination of more precise guidelines surrounding RE. This discrepancy is reflected 
in reports indicating that approximately 50% of adults meet the AE guidelines, yet only 20% 
meet the RE guidelines, and even fewer meet both guidelines based on self-report.4
There is strong evidence that AE contributes to the improvements in known CVD risk 
factors including blood lipids, hemodynamics, and cardiorespiratory fitness.5 There is also 
growing evidence that RE improves other CVD risk factors such as glucose metabolism, 
insulin sensitivity, and muscular strength and mass.5 Other potential mechanisms by which 
RE prevents CVD are through improved weight management,6 endothelial function,7 and 
hemodynamics.8,9 Results from previous studies conducted in patients with metabolic 
dysfunction (e.g., diabetes) have suggested that performing both AE and RE has greater 
benefits on metabolic health than performing either exercise alone.10–12 However, most 
studies examining CVD biomarkers especially in healthy adults have had limitations 
including short intervention durations (8–12 weeks), sample sizes of less than 30 per group, 
lack of a control group, or having the combined exercise group workout for twice as long 
compared to AE- or RE-only groups.13–17 Therefore, it is uncertain whether the added 
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benefits of combined exercise simply reflect the extra exercise time performed by that group 
and if these benefits are sustainable in the long term.
“Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise 
(CardioRACE)” is being conducted to address the limitations of previous studies and to find 
the most effective type of exercise for CVD prevention. CardioRACE is a 1-year randomized 
controlled exercise intervention wherein 406 participants who are at-risk of CVD were 
randomly assigned to 1 of 4 groups: 1) resistance exercise only (RE), 2) aerobic exercise 
only (AE), 3) combined resistance and aerobic exercise (CE), or 4) no exercise control 
(CON). The exercise groups are time-matched (same exercise time) and engage in 
supervised exercise 3 times per week for 60 minutes each session for 1 year. Daily physical 
activity and dietary intake is monitored in all groups throughout the year. The primary 
outcome is a composite z-score calculated using well-established traditional CVD risk 
factors including resting blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), 
fasting blood glucose, and percent body fat, which represent hypertension, 
hypercholesterolemia, diabetes, and obesity, respectively, which are all well-documented 
major CVD risk factors.18,19 We also plan to investigate each CVD risk factor separately, 
especially BP, since all participants have elevated or high BP at baseline. In addition, we will 
explore other traditional and emerging CVD risk factors and biomarkers such as 
cardiorespiratory fitness, muscular strength, central hemodynamics (e.g., central blood 
pressure and arterial stiffness), and over 40 different inflammatory markers. All these 
outcomes are measured at baseline, 6-months, and 12-months. The primary aim of 
CardioRACE is to evaluate the independent and additive (combined) effects of RE and AE 
training on overall CVD risk factors. Specifically, we hypothesize that RE-only and AE-only 
will have independent beneficial effects on composite z-scores through different pathways 
compared with the CON and that CE training will have a greater additive improvement on 
composite z- scores, compared with either RE or AE alone.
Busy middle-aged adults report that they have no time to exercise.20 The simple message 
from CardioRACE, a time-matched exercise intervention, could be that replacing half of 
their normal AE with RE, rather than doubling their exercise time by adding more RE, 
produces larger and more comprehensive total CVD benefits. However, regardless of its 
findings, CardioRACE will expand our understanding of the roles of RE, independent of and 
combined with AE, for CVD prevention. Furthermore, this study will address an important 
gap surrounding the potential mechanisms underlying RE’s effects, apart from or in 




CardioRACE completed recruitment and enrollment of 406 adults in Year 3 of the study, but 
the exercise intervention and outcomes’ assessments are currently ongoing. At baseline, 
participants were inactive, non-smoking men and women between 35–70 years old who 
were overweight or obese (body mass index [BMI] of 25–40 kg/m2) with elevated or high 
BP (resting systolic BP [SBP] of 120–139 mmHg or resting diastolic BP [DBP] of 80–89 
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mmHg), but not taking antihypertensive medications. These individuals had at least 3 risk 
factors (overweight, inactive, elevated BP) for CVD and were thus expected to gain the most 
cardiovascular benefits from this study.21 While individuals with stage II hypertension 
(≥140/90mm Hg) were excluded considering the safety of the study, participants with 
controlled diabetes (hemoglobin A1c ≤7.0%) or hypercholesterolemia were included for the 
generalizability. Individuals with elevated BP (120–139/80–89 mm Hg), are more likely to 
have comorbid conditions such as diabetes or high cholesterol, so including these conditions 
increases the generalizability of the results to the large segment of the population who have 
elevated BP or stage I hypertension.
All participants were willing and able to provide written informed consent. The study was 
approved by the local institutional review board and is registered at www.clinicaltrials.gov 
(ID: NCT03069092). The inclusion and exclusion criteria for CardioRACE are listed in 
Table I.
Recruitment and Screening Procedures:
CardioRACE recruited community-dwelling adults who mostly reside within 20 miles of the 
study center (Iowa State University in Ames, Iowa) since participants attend supervised 
exercise sessions at the center three times per week for 12 months. Recruitment strategies 
included attending health fairs and community events, providing health screenings to local 
businesses and organizations, working with local human resources professionals and 
worksite wellness coordinators, posting recruitment materials throughout the community, in 
health clinics, and on campus, advertising through local media outlets, emailing listservs, 
and mailing recruitment materials to households within the recruitment radius.
Interested individuals were provided information about the study and were screened for 
initial eligibility criteria (i.e., age, medication use, height, weight, physical activity, disease 
status) either through telephone screening or information sessions that were open to the 
public. Eligible participants were then invited to an orientation session where they learned 
more about the study, provided informed consent, and completed additional screening 
measures including medical history and physical activity readiness questionnaires, as well as 
height, weight, and BP assessments.
Following the orientation visit, participants visited the testing center for five education 
sessions to learn about general health education topics as well as study-specific protocols 
before baseline assessment. BP as an inclusion criteria was assessed during the orientation 
and the first three education visits. A series of four BP measurements in each visit was 
collected with a one-minute rest between readings. The four readings were averaged, and at 
least two out of the four visits had to meet SBP and DBP inclusion criteria in order for 
participants to proceed to the remaining two visits. After the run-in period, participants 
completed two days of baseline medical assessments and were then randomized to their 
study groups. See Figure 1 for a diagram of the participant flow from screening to 
randomization.
CardioRACE screened 1,850 interested individuals and randomized 406 participants into 
experimental groups (102 into resistance; 101 into aerobic; 101 into the combination; and 
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102 into the control). The baseline characteristics of the study participants are depicted in 
Table II. There were no significant group differences in the main eligibility criteria at 
baseline (all P > 0.05). However, interim data analyses are not allowed in this study, so full 
baseline characteristics including all outcome variables will be provided after completing the 
study.
Study Outcomes:
The primary outcome is the change from baseline to 12-month follow-up in the composite 
CVD risk score (z-score) calculated using resting BP, LDL-C, fasting glucose, and percent 
body fat. These four variables represent primary modifiable CVD risk factors included in the 
Atherosclerotic CVD (ASCVD) risk algorithm developed by the American Heart 
Association (AHA) and American College of Cardiology (ACC).22,23 In addition, these 
factors represent the four major modifiable health conditions— hypertension, 
hypercholesterolemia, diabetes, and obesity—identified by the AHA, ACC, and Centers for 
Disease Control and Prevention (CDC) that increase the risk for CVD.23–25
In general, individuals at high risk of developing CVD have a cluster of risk factors 
influenced by numerous physiological systems and functions (e.g., hemodynamic, blood 
lipids, glucose metabolism, and adiposity) rather than a single risk factor. Therefore, overall 
CVD risk score, which quantifies and predicts future CVD risk, is widely used from both 
clinical and public health perspectives (e.g., Framingham CVD risk score) in CVD 
prevention.26 Most people will likely show significant improvements in some CVD risk 
factors, but not all CVD risk factors, and the combination of improvements will vary 
between individuals. Thus, focusing on a single CVD risk factor may not fully explain the 
cumulative or comprehensive benefits of exercise that can affect multiple physiological 
systems and functions. The composite CVD risk score is especially useful when comparing 
the total effectiveness of different types or combination of exercise. For example, AE has 
been shown to improve hemodynamics (e.g., blood pressure) and blood lipid profile (e.g., 
LDL-C) to a greater degree than RE, but RE might be relatively more beneficial for 
improving glucose metabolism (e.g., fasting glucose) and body composition (e.g., muscle 
mass and percent body fat) as depicted in Figure 2. However, there is very little evidence, 
and we still do not know what type or combination of exercise is best for the prevention of 
the clinical outcome of CVD such as heart attack or stroke instead of its single risk factor 
(e.g., hypertension or diabetes). The composite score in CardioRACE will inform what type 
or combination of time-matched exercise is comparatively most effective for improving the 
overall CVD risk profile in middle-aged adults who are at high risk of developing CVD. We 
will also investigate the changes in each of these risk factors (resting BP, LDL-C, fasting 
glucose, and percent body fat) separately, as assessing individual CVD risk factors will be 
important to compare our results to previous studies that mostly focused on a single CVD 
risk factor (e.g., blood pressure). Other outcomes of interest include changes in emerging 
CVD risk factors such as arterial stiffness, cardiorespiratory and muscular fitness, 
inflammatory markers, waist circumference, body composition (e.g., muscle mass), and 
bone mineral density.
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Assessment Day 1: All outcomes are assessed over two study visits at baseline, 6-
months, and 12-months. Day 1 occurs in the morning after a minimum 12-hour fast during 
which participants do not drink or eat anything besides plain water. Participants are also 
instructed to avoid exercise and alcohol within 48 hours of the appointment. Participants do 
not take over-the-counter medications within 24 hours or prescription medications the 
morning of the visit.
Lifestyle and psychosocial factors are assessed with a detailed questionnaire. Variables 
assessed include demographics, medical history, medication use, physical activity, smoking, 
alcohol intake, health-related quality of life (SF-36),27 stress (Perceived Stress Scale),28 
depression (Beck Depression Inventory-II),29 anxiety (Trait Anxiety Inventory),30 and sleep 
quality (Pittsburgh Sleep Quality Index).31
Peripheral SBP and DBP are measured following a minimum of 10 minutes of seated rest 
using the Omron HEM-907xl automated digital BP monitor (Omron Healthcare, Inc., Lake 
Forest, IL). Following AHA guidelines,2 participants are instructed to not talk and to sit 
back comfortably in the chair with their lower back supported and feet uncrossed during 
readings. A brachial pressure cuff is placed around their supported left arm at the level of the 
atria. The research assistant exits the room and the BP device takes three measurements with 
2 minutes of rest between each BP measurement.
Central SBP and DBP, resting heart rate (HR), and arterial stiffness are assessed using the 
SphygmoCor XCEL (AtCor Medical, Itasca, IL, USA) automated oscillometric device. 
Central BP and resting HR are assessed following the same procedures as peripheral BP 
except the participant is in the supine position instead of seated. Arterial stiffness is assessed 
via carotid-femoral pulse wave velocity (PWV) following the AHA recommended 
guidelines.32
Anthropometric measurements are taken without shoes and in laboratory-provided attire 
(scrubs). Height (meter) and weight (kg) are assessed using a standard stadiometer and 
digital scale (SECA 769, Hamburg, Germany), respectively. Waist circumference (cm) is 
measured against the skin at the level of the umbilicus using inelastic tape. Height, weight, 
and waist circumference measurements are performed in duplicate and the average value is 
used. Body Composition, including fat mass, muscle mass, bone mineral density, and 
percent body fat, is measured using the Hologic Horizon dual x-ray absorptiometry (DXA) 
machine (Hologic, Inc., Marlborough, MA, USA) following standard procedures.33
Blood chemistry, including blood lipids and lipoproteins (total, high-density (HDL), and 
LDL-C, and triglycerides), fasting glucose and insulin, hemoglobin A1c, and over 40 
inflammatory markers (e.g., cytokines, chemokines, and growth factors), is analyzed using 
blood collected from the antecubital vein after a minimum 12-hour overnight fast.
Assessment Day 2: Day 2 occurs in the afternoon since it involves non-fasted physical 
fitness tests. Like Day 1, participants are instructed to avoid exercise and alcohol within 48 
hours of the appointment.
Brellenthin et al. Page 6













Following the same procedures described above, peripheral SBP and DBP are also measured 
during day 2 to account for day-to-day and time-of-day variability as well as fasted versus 
non-fasted status. The mean BP from day 1 and the mean BP from day 2 are averaged to 
calculate BP at baseline, 6- months, and 12-months.
Physician-supervised cardiorespiratory fitness (VO2max) is assessed using a maximal graded 
treadmill test based on the Balke & Ware protocol, which is considered valid and safe for 
high-risk participants.34 Participants were familiarized with the testing procedures during 
one of the run-in sessions. Following the American College of Sports Medicine’s (ACSM) 
guidelines for exercise testing, participants wear a HR monitor (Polar, Lake Success, NY) 
and expire through a tube attached to a Physio- dyne Max-TT metabolic cart (Fitness 
Instrument Technologies, Quogue, NY).35 The grade increases by 1% per minute with the 
speed fixed at 88 m/min (3.3 mph) until volitional fatigue.34 HR and gas exchange variables 
including VO2, CO2, ventilation, and respiratory exchange ratio (RER) are recorded every 
30 seconds. Perceived exertion using the Borg 6–20 scale is assessed every other minute and 
at volitional fatigue. Valid VO2max values will be identified using ACSM criteria (e.g., RER 
≥ 1.1, plateau in VO2 or HR with increasing workload, RPE > 17) and considered in 
analyses of cardiorespiratory fitness.
Muscular strength is determined for both upper and lower body by a one repetition 
maximum (1-RM) protocol using the chest and leg press machines (Technogym, 
Gambettola, Italy), respectively following the National Strength and Conditioning 
Association (NSCA) guidelines.36 Participants perform 3 warm-up sets of 10, 5, and then 2–
3 repetitions of successively higher weights separated by 2 minutes of rest each. Participants 
then perform a series of 1-RM attempts in 5–10 pound increments, with 2–4 minutes of rest 
between trials. The final maximal weight lifted successfully is considered the participant’s 
absolute 1-RM. Grip strength is assessed using a digital hand dynamometer (Jamar Plus+; 
Patterson Medical, St. Paul, MN, USA). Participants sit in a chair with their arm at their side 
and elbow at a 90-degree angle. Participants perform 3 maximal contractions separated by 
30 seconds for both the left and right hands, and the average of the highest value from each 
hand is used. However, other methods (e.g., the highest, average from all tests) will also be 
considered since there is no universal consensus.
Randomization:
Following baseline assessments, eligible participations are randomized. The randomization 
sequence was generated by the study statistician using a computer program. Randomization 
follows a stratified block design using sequences of permuted blocks of equal length that 
contained the treatment assignments (RE, AE, CE, or CON) in random order. The pre-
defined strata were based on sex (male or female), race/ethnicity (non-Hispanic white or all 
other races and ethnicities), age (35–44, 45–54, 55–64, or 65–70 years), and baseline BMI 
(<30, 30–34, or 35–40 kg/m2). Group allocations are concealed in opaque envelopes that are 
opened by participants in front of intervention staff during a separate study visit.
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All assessment staff are separated from the exercise intervention. The assessment team is 
blinded to the group assignments and consists of study staff who conduct and collect all 
baseline and follow-up data. Participants are instructed to not reveal their group assignment 
to the assessment team during testing. In addition, the primary CVD-related outcomes of the 
study such as BP and blood lipids are assessed using an automated BP monitor or are 
analyzed by an independent laboratory (Quest Diagnostics, Secaucus, NJ, USA), 
respectively, which greatly reduces the potential for human error or bias. The data manager 
is also blinded to group assignments, and double entry of data is performed to check for 
accuracy. The exercise intervention team consists of staff members who communicate 
directly with participants and who prescribe, track, and supervise exercise following the pre-
programmed, computer-controlled, standardized exercise prescription in each exercise 
group. They are not involved in outcomes assessment or data entry.
Exercise Interventions and Control:
The RE, AE, or CE interventions are matched for time (180 min/week) and frequency (3 
days/week for 60 minutes each session including 50 minutes of RE, AE, or CE and 5 
minutes each of warm-up and cool-down exercises). The 2018 PAG recommend 150 minutes 
of moderate-intensity or 75 minutes of vigorous-intensity AE per week (equal to ≥500 MET-
min/week), and ≥2 days of RE per week.3 In CardioRACE, the RE training meets the RE 
guidelines only, the AE training meets the AE guidelines only, and the combined RE plus 
AE training meets both guidelines. The guidelines provide more detailed recommendations 
for AE, yet provide relatively simple guidelines for RE, partly due to limited evidence and 
difficulty of accurately tracking and reporting RE data (e.g., intensity), especially in 
observational studies.
All exercise sessions are supervised by senior staff members and trained research assistants 
to encourage participants to complete the sessions, provide feedback, and supervise the 
actual training. However, exercise prescriptions are delivered through and automatically 
recorded using the Technogym Wellness System (Technogym, Gambettola, Italy). Each 
participant is assigned a key that stores their unique, individualized workout prescription that 
is programmed by staff considering their fitness levels and progression. Participants check-in 
using their key at a computer kiosk, which records attendance automatically. After checking 
in, the participant inserts their key into each exercise machine, and their workout 
prescription is loaded onto the machine (e.g., treadmill speed and grade are automatically 
controlled and adjusted following the stored exercise program in their key and each 
participant’s HR during exercise). After each exercise, workout performance data (e.g., HR, 
duration, sets, repetitions, pounds lifted) are stored in the key. Participants check-out with 
their key, and their exercise data are transmitted back to the local database that follows 
confidentiality and safety regulations based on the study IRB and Data Safety and 
Monitoring Board (DSMB) protocols. Staff help ensure the safety of the participants, their 
compliance with the exercise prescriptions, and accurate transmission of exercise data to 
servers. Staff also communicate directly with participants at each session to improve 
adherence and update exercise prescriptions as fitness levels change. With this detailed 
exercise data from a 12-month intervention, it will be possible to provide specific details 
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regarding exercise parameters for various CVD-related biomarkers as described earlier,37 
which will better inform future physical activity recommendations for both resistance and 
aerobic exercise. This is a novel strength of the study for accurate exercise data collection as 
well as exercise attendance and compliance calculation, which is important for the 
interpretation of the outcome data between groups and individuals.
Resistance Exercise (RE): The RE group performs 3 sets of 8–16 repetitions at 50–80% 
of 1-RM on each of 12 machines (see Table III for a list of the machines). The first 8 weeks 
of the program, participants perform more repetitions (16–20) at a lower weight (30–40% of 
1-RM) for fewer sets (1–2 sets) to become familiar with the exercise program and to prevent 
potential injuries and severe muscle soreness. Participants rest a minimum of 1 minute 
between sets and between different machines. Strength is re-evaluated every 8 weeks using 
estimated 1-RM protocols, so that exercise prescriptions are continuously updated 
throughout 1 year. This continuous individualized strength evaluation and progressive 
prescription is important to prevent a possible decrease in CVD benefits at later months that 
is commonly observed in most exercise intervention studies.
Aerobic Exercise (AE): Aerobic prescriptions are based on 50%–80% of heart rate 
reserve (HRR) following a gradual progression in duration (20–50 minutes) and intensity 
throughout the first 8 weeks. Maximum HR (from the treadmill test) and resting HR from 
baseline assessments are used for AE prescriptions. Resting HR is re-assessed every 8 
weeks, so that HRR prescriptions can be continuously updated through 1 year. Each session, 
participants have their choice of performing aerobic exercise on 2 machines (2, 25-minute 
segments) including upright or recumbent bicycles, elliptical machines, or treadmills. 
Participants wear a HR monitor (Polar, Lake Success, NY), and HR prescriptions are 
assigned to the participant’s Technogym key. The Technogym key communicates with each 
machine to adjust the speed, grade, and/or resistance on the aerobic equipment in order to 
keep participants within the prescribed HR range, which is programmed to gradually 
increase from 50% to 80% HRR.
Combination Exercise (CE): CE is matched for time with the RE and AE groups (3 
times per week for 60 minutes each time); however, the RE and AE training protocols are 
truncated by half so that participants perform 2 sets instead of 3 sets at the same intensity 
(50–80% 1-RM) on 9 machines instead of 12 machines and 25 minutes of aerobic exercise 
at the same intensity (50%–80% HRR). As with the RE and AE protocols, muscular strength 
and resting HR are re-evaluated every 8 weeks to update the RE and AE prescriptions 
throughout 1 year.
Control Group (CON): The delayed exercise group serves as the control group. They do 
not perform exercise at the study center during the first 12 months of their participation, but 
they are offered their choice of RE, AE, or CE for 12 months (in year 2) after their first year 
of no exercise in order to help prevent dropout, which can occur more often in a no exercise 
control group. Any data collected from the control group’s optional year of exercise (in year 
2) will not be included in the primary data analyses described in this paper. Since the 
primary outcomes are predominantly physiological (e.g., blood pressure and cholesterol) 
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rather than psychological (e.g., depression and quality of life), we chose not to use a more 
involved control group design (e.g., health education classes, stretching), which may better 
control for the potential effects of human interaction on the outcomes. Furthermore, it was 
not clear what the effects of a year of health education or stretching would be on the variety 
of primary and secondary outcomes in CardioRACE making it difficult to interpret the 
results of exercise training. To increase staff contact during their first 12 months of 
participation when they are not exercising, control group participants receive diet education 
and in-person counseling (described below) and communicate with staff at least weekly. See 
Table III for an outline of exercise prescriptions for each group.
Dietary Counseling and Monitoring:
Participants in all four groups receive Dietary Approaches to Stop Hypertension (DASH) 
Diet education during the run-in period and have individual dietary counseling appointments 
with a registered dietitian at 3-, 6-, 9-, and 12-months throughout the intervention. The 
DASH is an evidence-based heart-healthy diet plan that recommends reducing sodium intake 
to <2,300 mg per day while increasing intake of magnesium, potassium, and calcium. DASH 
also recommends consuming fruits and vegetables, whole grains, lean protein and meat, fat-
free or low-fat dairy, and nuts and seeds, which is largely consistent with the Dietary 
Guidelines for Americans.38 Participants complete an automated, computer-based 24-hour 
food recall on 3 random days per month (2 weekdays [Monday-Thursday] and 1 weekend 
day [Friday-Sunday]) throughout the 12 months. Dietary intake data were collected and 
analyzed using the Automated Self-Administered 24-hour (ASA24) Dietary Assessment 
Tool, version (2016, 2018), developed by the National Cancer Institute, Bethesda, MD.39 
During the individual diet counseling sessions, participants review their past food recalls and 
set dietary goals with the dietitian. Most exercise intervention studies focused solely on the 
effects of exercise without considering the benefits of diet counseling. However, considering 
both exercise and diet is a more effective and comprehensive behavioral approach from both 
clinical and public health perspectives and is a unique strength of the study. We provide the 
same diet counselling for all participants, so that the difference in changes in outcome 
variables between groups are induced by exercise intervention only. In addition, the effect of 
DASH diet education on the outcome variables will be analyzed in the control group by 
comparing the pre- and post-outcome data.
Physical Activity Monitoring:
Participants in all groups are instructed to not engage in structured aerobic or resistance 
exercise outside of the center throughout the duration of their participation. Participants are 
provided with a triaxial accelerometer-based pedometer (Omron HJ-321), which they wear 
during waking hours for the entire 12 months. Participants do not wear the pedometer during 
supervised exercise at the center. Daily step counts and wear times as well as participation in 
any muscle-strengthening activities are recorded weekly and checked by research staff. 
Exercise intervention studies often have measured outside lifestyle physical activity at the 
beginning and end of the intervention, but not during the entire intervention period. This 
limitation may cause confounding bias because exercise study participants are highly 
motivated to be active outside the study center. In this study, we monitor total daily activity 
for all participants during the entire 1-year intervention using accelerometers.
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Completers are defined as participants who participate in both baseline and 12-month 
assessments, as these data collection points are included in the primary statistical analyses. 
Dropouts are defined as those who do not complete 12-month assessments. Because 100% 
adherence to the exercise protocol is unrealistic over a 1-year long period due to factors such 
as sickness, family obligations, and travel, CardioRACE defines acceptable adherence to the 
study protocol as completing ≥80% of the total amount of exercise prescribed in each group 
in this large (N=406) clinical trial. If a participant has not reached ≥80% adherence by the 
end of the 12 months, they are given the option of completing up to another 4 weeks (extra 1 
month) of exercise sessions prior to their final 12-month follow-up assessments following 
earlier studies.11,40 Both completers and dropouts will be included in the primary intention-
to-treat analyses, and the ≥80% attendance rate will be used to identify participants included 
in the treatment efficacy analyses. Also, we will consider other benchmarks (e.g., 70% or 
90% attendance) in additional analyses.
CardioRACE employs various strategies to minimize dropouts and maximize adherence. 
Similar to other extended exercise interventions, there is a month-long run-in period between 
the first study visit and the randomization visit.10,40 Participants attended an orientation, 5 
education sessions, and baseline assessments within a 5-week period in order to be eligible 
for randomization. These visits served several purposes including multiple measurement of 
BP to determine eligibility, instruction regarding study protocols (e.g., how to use ASA24 
diet recall system), and ascertainment of the participant’s ability to come to the center 
regularly. Throughout the exercise intervention, participants receive reports every 8 weeks 
on their attendance, average daily step counts, strength and/or resting HR changes, and total 
distance traveled (e.g., from bike and treadmill) and/or weight lifted during their 
participation that are important to improve exercise and study compliance. They also receive 
birthday and holiday cards as well as monthly newsletters. CardioRACE incorporates 
motivational interviewing techniques during randomization and the 6-month assessment, 
behavioral contract signing, flexible exercise scheduling, and adherence monitoring to 
further improve study compliance. Participants receive an encouragement phone call, called 
an “I care call,” once per month from a staff member and are provided the opportunity to 
discuss their study experience and to problem solve any issues. Participants are also assigned 
one primary staff person as their principal contact (“CardioRACE coach”) for study-related 
concerns. If a participant has two unexcused absences in a row, they are contacted by their 
exercise coach to discuss and find solutions to any potential barriers. Participants are 
expected to make-up unexcused absences by coming to the center another time that week.
Each participant is given up to $300 as an incentive to complete the study. Participants are 
remunerated $60 for each baseline, 6-month, and 12-month assessment ($180). They receive 
an additional $60 at each the 6-month and 12-month assessment ($120) if they have 
provided at least >80% of their step counts and diet recalls in the previous 6 months.
Data Analysis:
Power computations were based on detecting a significant group-by-time interaction for the 
composite CVD risk z-score (primary outcome), using a linear mixed effects model (4 
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groups X 2 times: baseline and 12-month follow-up) with a=0.05, power=0.99, and α small-
to-medium effect size (Cohen’s f effect size of 0.19) from an 8-week pilot study. It was 
estimated that 200 total participants (50 in each of the four groups) would be needed to 
observe significant group-by-time effects on the composite CVD score. To be able to further 
detect group differences in pairwise comparisons (e.g., CE v. AE) and to account for 
anticipated participant attrition (an estimated 10%), diminished compliance over a 1-year 
intervention, as well as potential changes in confounding factors (e.g., changes in 
medication, weight, or outside physical activity) over 1 year, the sample size was increased 
to 400, which was confirmed by the biostatistician of the study.
The primary outcome, the composite z-score, will be the mean of the z-scores of the four 
CVD risk factors: resting BP, LDL-C, fasting glucose, and percent body fat. Each risk factor 
will be individually standardized and expressed as a z-score by using the formula = (value - 
mean)/standard deviation for each participant. The means and standard deviations used to 
create the z-scores for each risk factor at both baseline and follow-up will be the values from 
the entire sample at baseline. The primary outcome will be analyzed using the intention-to-
treat principle and will include all participants as randomized. The potential effects of 
missing data will be explored through various imputation models and sensitivity analyses. 
We will also consider the effects of medications that affect LDL-C (e.g., statins) or glucose 
(e.g., insulin), which factor into the composite score. Analyses will take into account 
covariates including age, sex, BMI, and baseline values of each outcome measure. Linear 
mixed-effects models for repeated measures with effects for time (baseline and 12-month 
follow-up), experimental group, and group-by-time interaction will be used. If the p-value 
for the group-by-time interaction is less than 0.05 (significant), we will adjust for multiple 
comparisons to estimate confidence intervals and p-values for the six pre-specified inter-
group contrasts: 1) RE vs. CON, 2) AE vs. CON, 3) CE vs. CON, 4) CE vs. RE, 5) CE vs. 
AE, and 6) RE vs. AE for changes in composite z-scores and individual risk factors between 
baseline and 12-month follow-up. Additional analyses will examine treatment efficacy in the 
subgroup of adherent participants; evaluate treatment mediators (e.g., changes in diet, 
medication, and weight during intervention),’the sensitivity of results after omitting those 
with diabetes or lipid-lowering medications; assess the impact of incomplete data due to 
attrition; and examine treatment response at 6 months to evaluate the trends of exercise 
effects. Results from these additional analyses will be considered exploratory and will be 
interpreted with caution due to their inflation of the Type I error rate. Data will be assessed 
for normality, and any skewed data could be transformed or analyzed non- parametrically. 
All p-values will be two-sided, and p<0.05 will be considered statistically significant using 
SAS software version 9.4 (SAS Institute, Cary, North Carolina).
This study is supported by the National Heart, Lung, and Blood Institute (R01HL133069). 
The authors are solely responsible for the design and conduct of this study, all study 
analyses, the drafting and editing of the paper and its final contents.
DISCUSSION
Cardiovascular disease is the leading cause of death in the US and is estimated to cause one-
third of deaths globally.1,41 The 2018 PAG Advisory Committee Scientific Report stated that 
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there was strong evidence demonstrating a significant inverse relationship between 
moderate-to-vigorous intensity aerobic PA and incidence of CVD. However, as was the case 
in the first 2008 PAG Scientific Report ten years ago, there remains insufficient data to 
comment on the relationship between muscle-strengthening activities, independent of and 
combined with aerobic PA, and CVD-related outcomes.42 There is a clear research need to 
delineate the unique and possibly additive benefits of resistance exercise alone or alongside 
traditional aerobic exercise in the prevention of CVD, specifically for those who are at high-
risk.
In response, CardioRACE is an adequately powered, supervised randomized, controlled trial 
of exercise on CVD risk factors and biomarkers. CardioRACE will evaluate the effects of 
performing exercise meeting the RE guidelines only, the AE guidelines only, or both the RE 
and AE guidelines compared with a no exercise control group. Important strengths of this 
study include: 1) 1-year long exercise intervention with a comparative effectiveness (multi-
factorial) and exercise time-matched study design; 2) comprehensive and gold-standard 
measurement of both traditional and emerging CVD risk factors such as BP, blood lipids, 
arterial stiffness, body composition, cardiorespiratory fitness, muscular strength, bone 
mineral density, and comprehensive inflammatory markers; 3) extensive monitoring of 
lifestyle factors such as diet (DASH) and lifestyle PA to control potential confounders 
throughout the 1-year intervention period; 4) precision and control over individual exercise 
programming and monitoring using an innovative computer-based exercise training system 
(Technogym Wellness System) to minimize a potential bias by research staff, 5) continuous 
and progressive adjustments for individualized exercise prescription (an increase of exercise 
intensity) to account for fitness changes every 2 months throughout the intervention; and 6) 
recruitment of 406 high-risk individuals with 3 known risk factors for CVD (overweight or 
obese, inactive, and elevated or high untreated BP) that has significant clinical and public 
health implication and impact. Following all these novel methodological approaches, we 
believe that this study will provide reliable and meaningful data, which can contribute to 
future physical activity recommendations.
Summary:
CardioRACE will answer one of the most commonly asked questions about exercise and 
health, “What type and combination of exercise is most effective for cardiovascular 
benefits?” by comparing the effects of RE, AE, and CE, to improve a wide array of CVD 
risk factors among participants with established CVD risk factors. CardioRACE will yield 
evidence-based exercise data that can be used by both patients and clinicians, responding to 
the need for knowledge and information about exercise and CVD prevention.
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Figure 1: Participant flow from initial screening to randomization
Abbreviations: BMI, body mass index; BP, blood pressure; RE, resistance exercise training 
only; AE, aerobic exercise training only; CE, combined aerobic and resistance exercise 
training; CON, no-exercise control group.
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Mechanistic pathway between resistance, aerobic, or combined exercise training and 
cardiovascular disease (CVD)
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Table I:
Inclusion and exclusion criteria
Inclusion criteria:
 • Men and women between 35–70 years old
 • Non-smoking
 • Body mass index between 25–40 kg/m2 (or BMI between 23–40 kg/m2 for Asian individuals)
 • Inactive (not meeting the aerobic and resistance exercise guidelines over the past 3 months)
 • Systolic blood pressure of 120–139 mm Hg or diastolic blood pressure of 80–89 mm Hg
 • Not on antihypertensive medications
Exclusion criteria:
 • Significant cardiovascular disease such as:
  ○ Unstable coronary heart disease or decompensated heart failure
  ○ Severe pulmonary hypertension, aortic stenosis, or uncontrolled arrhythmias
  ○ Acute myocarditis, endocarditis, pericarditis, or aortic dissection
  ○ Previous myocardial infarction or stroke
  ○ Pacemaker or other implanted device
 • Other medical conditions that are life-threatening or that can interfere with or be aggravated by the exercise training such as:
  ○ Cancer, requiring treatment in the past 5 years
  ○ Autoimmune diseases
  ○ Uncontrolled diabetes mellitus (hemoglobin A1c > 7.0%)
  ○ Severe arthritis or mobility limitations
 • Severe depression (Beck Depression Inventory-II Score ≥ 29)
 • > 4 weeks of travel planned during the intervention period
 • Unexplained or irregular weight loss or gain of more than 5% body weight over the previous 6 months
 • Women who are pregnant or who plan to become pregnant in the next year
Abbreviations: BMI, Body mass index (kg/m2)
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Table II:
Baseline eligibility characteristics of the study participants by experimental group
Variable All Resistance Aerobic Combination Control p-value
N 406 102 101 101 102
Female, n (%) 216 (53) 53 (52) 53 (52) 55 (54) 55 (54) 0.98
Racial or ethnic minority, n (%)
a 85 (21) 22 (22) 21 (21) 21 (21) 21 (21) 1.00
Age (years) 50.3 (9.9) 49.8 (10.4) 50.3 (9.8) 50.5 (9.5) 50.4 (9.8) 0.96
BMI (kg/m2) 31.2 (4.9) 31.5 (5.2) 31.2 (4.8) 31.1 (5.0) 31.2 (4.8) 0.94
Systolic BP (mm Hg) 126.0 (11.2) 126.0 (11.2) 125.9 (10.3) 126.6 (11.6) 125.5 (11.7) 0.88
Diastolic BP (mm Hg) 81.7 (8.2) 82.2 (7.8) 81.4 (8.1) 82.1 (8.9) 81.1 (8.1) 0.62
Data are presented as mean (SD) unless indicated otherwise. Baseline group differences in continuous variables analyzed using one-way ANOVA; 
categorical variables analyzed using X2 tests.
a
Participants identifying as American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, and/or Native Hawaiian or 
other Pacific Islander. Abbreviations: BMI, body mass index; BP, blood pressure.
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Table III:
Exercise parameters for each group
Group Frequency Duration Intensity Type
Resistance 3 times per week 60 minutes 3 sets of 12 exercises at 50%–80% 1-RM*
Leg press, hamstring curl, quadriceps 
extension, hip abduction, chest press, lat 
pulldown, shoulder press, biceps curl, triceps 
extension, abdominal crunch, lower back 
extension, and torso rotation
Aerobic 3 times per week 60 minutes 50%–80% heart rate reserve Upright or recumbent bike, elliptical, and treadmill
Combination 3 times per week
60 minutes (30 min 
aerobic plus 30 min 
resistance)
Resistance: 2 sets of 9 
exercises at 50%–80% 1-RM 
Aerobic: 50%−80% heart rate 
reserve
Resistance: Leg press, hamstring curl, 
quadriceps extension, chest press, lat pulldown, 
abdominal crunch, lower back extension, and 
torso rotation
Aerobic: Upright or recumbent bike, elliptical, 
and treadmill
Control No exercise training
Abbreviations: 1-RM, 1-repetition maximum
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